Open Access<p>Design and Development of a Behaviorally Active Recombinant Neurotrophic Factor</p>
Author(s) -
Nicholas J Pekas,
Jason L. Petersen,
Monica Sathyanesan,
Samuel S Newton
Publication year - 2020
Publication title -
drug design, development and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.964
H-Index - 64
ISSN - 1177-8881
DOI - 10.2147/dddt.s274308
Subject(s) - erythropoietin receptor , neurotrophic factors , erythropoietin , brain derived neurotrophic factor , neurotrophin , tropomyosin receptor kinase b , pharmacology , chemistry , biology , microbiology and biotechnology , receptor , biochemistry , endocrinology
Carbamoylated erythropoietin (CEPO) is a chemically engineered, nonhematopoietic derivative of erythropoietin (EPO) that retains its antidepressant and pro-cognitive effects, which are attributed to the increased expression of neurotrophic factors like brain derived neurotrophic factor (BDNF), in the central nervous system. However, the chemical modification process which produces CEPO from erythropoietin (EPO) requires pure EPO as raw material, is challenging to scale-up and can also cause batch-to-batch variability. To address these key limitations while retaining its behavioral effects, we designed, expressed and analyzed a triple, glutamine, substitution recombinant mimetic of CEPO, named QPO.